TARO-AMPHOTERICIN B LIPOSOMAL 50 MG
AMPHOTERICIN B : 50 MG · DIN 02554186 · TARO PHARMACEUTICALS INC
Health Canada status: APPROVED
What is TARO-AMPHOTERICIN B LIPOSOMAL?
TARO-AMPHOTERICIN B LIPOSOMAL 50 MG contains AMPHOTERICIN B : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02554186, held by TARO PHARMACEUTICALS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 20-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02554186 |
|---|---|
| Brand name | TARO-AMPHOTERICIN B LIPOSOMAL |
| Generic / active ingredient | AMPHOTERICIN B : 50 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 50 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AA01 AMPHOTERICIN B |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 20-Dec-2024 |
What can be used instead?
Other Canadian products sharing ATC code J02AA01 AMPHOTERICIN B. 2 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMBISOME | 50 MG | POWDER FOR SOLUTION | ASTELLAS PHARMA CANADA INC | MARKETED | DIN 02241630 |
| FUNGIZONE | 50 MG | POWDER FOR SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 00029149 |
| ABELCET | 5 MG | SUSPENSION | LEADIANT BIOSCIENCES, INC | CANCELLED POST MARKET | DIN 02231590 |
| AMPHOTEC 100 MG | 100 MG | POWDER FOR SUSPENSION | THREE RIVERS PHARMACEUTICALS LLC | CANCELLED POST MARKET | DIN 02241749 |
| AMPHOTEC 50 MG | 50 MG | POWDER FOR SUSPENSION | THREE RIVERS PHARMACEUTICALS LLC | CANCELLED POST MARKET | DIN 02241750 |
| AMPHOTERICIN B FOR INJECTION, USP | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02405032 |
Who else supplies AMPHOTERICIN B worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMPHOTERICIN B appears in 24 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.